Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06832631

VITUS Post-Market Registry

To collect post marketing surveillance data on consecutive patients with peripheral arterial occlusive disease (PAOD) intended to be or treated by the VITUS peripheral drug-coated dilatation catheter when used according to the Instructions for Use and treating physician decision. Data will be collected in order to assess the long-term safety and performance of the VITUS peripheral drug-coated dilatation catheter in routine clinical practice.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Peripheral Arterial Disease Arterial Occlusive Diseases Arteriosclerosis Atherosclerosis Cardiovascular Diseases Peripheral Arterial Occlusive Disease Peripheral Arterial Occlusive Disease 1 Peripheral Vascular Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

AZORG, Aalst, Belgium

Loading trial locations.

About this study

The multicenter, prospective registry population consists of consecutive patients with peripheral arterial occlusive disease (PAOD) who undergo percutaneous transluminal angioplasty (PTA) intervention and are intended to be or treated by the VITUS peripheral drug-coated dilatation catheter (according to the Instructions for Use) as part of routine clinical care. Approximately 284 patients from approximately 15 centers in Europe will be entered into the registry. Patients entered into the registry are followed for three years. The registry is considered finished when all patients have completed the 36-month follow-up.

A follow-up is scheduled at the following timepoints: immediately post-procedure, 30 days, 6 months, 12 months, 24 months, and 36 months. Follow-up is obtained by telephone contact with the patient or at a planned hospital visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Consecutive patients intended to be or treated by the VITUS peripheral drug-coated dilatation catheter as per physicians' decision and according to IFU in the setting of routine clinical care are entered into the registry
  • The lesion to be treated should be shorter than the nominal length of balloon at a reference vessel diameter of 2.0 mm up to 7.0 mm.
  • If lesion is longer than the individual balloon, more than one DCB can be used for longer lesions with the mandatory overlapping balloons of 10mm to avoid any geographical miss.
  • Rutherford clinical categories 2-5

Exclusion criteria

  • The patients are excluded from registration if ANY of the following conditions apply:
  • High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons)
  • Currently participating in another investigational drug or device study in which a routine angiographic follow-up in peripheral arteries is planned
  • A life expectancy of <1year
  • Explicit refusal of participation in the registry
  • Residual stenosis >50% after vessel preparation

Treatment and study plan

Percutaneous Transluminal Angioplasty with a paclitaxel drug-coated balloon

Device

Balloon angioplasty for the treatment of symptomatic peripheral arterial disease with a paclitaxel drug-coated balloon

Primary outcomes

  1. Proportion of participants with Adjudicated freedom from major adverse events (MAE)

    Time frame: 30 days post-procedure (primary safety endpoint at 30 days)

    Adjudicated freedom from major adverse events (MAE), where MAE is defined as a composite of device- and procedure-related mortality, freedom from major target limb amputation, and freedom from clinically driven target lesion revascularization (cd-TLR)

  2. Proportion of participants with Adjudicated freedom from major adverse events (MAE)

    Time frame: 12 months post-procedure (primary safety and efficacy endpoint at 12 months)

    Adjudicated freedom from MAE, where MAE is defined as a composite of device- and procedure-related mortality through 30 days, freedom from major target limb amputation, and freedom from clinically driven target lesion revascularization (cd-TLR) within 12 months

  3. Occurrence of Adjudicated freedom from cd-TLR

    Time frame: 12 months post-procedure (primary efficacy endpoint at 12 months)

    Adjudicated freedom from cd-TLR, where cd-TLR is defined as any reintervention performed for ≥50% diameter stenosis (visual estimate) at the target lesion after documentation of recurrent clinical symptoms

Secondary outcomes

  1. Proportion of participants with Adjudicated freedom from MAE

    Time frame: 6 months

    Adjudicated freedom from MAE, where MAE is defined as a composite of device- and procedure-related mortality through 30 days, freedom from major target limb amputation, and freedom from clinically driven target lesion revascularization (cd-TLR) within 6 months

  2. Occurrence of Adjudicated freedom from cd-TLR

    Time frame: through hospital discharge (expected to be within 24 hours), at 30 days, 6 months, 24 months and 36 months

    Adjudicated freedom from clinically driven target lesion revascularization (cd-TLR)

  3. Occurrence of Adjudicated freedom from clinically driven target vessel revascularization (cd-TVR)

    Time frame: through hospital discharge (expected to be within 24 hours), at 30 days, 6 months, 12 months, 24 months and 36 months

    Adjudicated freedom from clinically driven target vessel revascularization (cd-TVR)

  4. Proportion of participants with Major amputation-free survival

    Time frame: through hospital discharge (expected to be within 24 hours), at 30 days, 6 months, 12 months, 24 months and 36 months

    Major amputation-free survival, defined as absence of target limb major amputation (above the ankle)

  5. Proportion of participants with Any amputation-free survival

    Time frame: through hospital discharge (expected to be within 24 hours), at 30 days, 6 months, 12 months, 24 months and 36 months

    Any amputation-free survival, defined as absence of any amputation in target limb

  6. Proportion of participants with Adjudicated freedom from MAE

    Time frame: through hospital discharge (expected to be within 24 hours), 6 months, 12 months, 24 months and 36 months

    Adjudicated freedom from MAE

  7. Change in Rutherford clinical category

    Time frame: 12 months

    Mean change in rate from baseline Rutherford clinical category (clinical assessment at hospital visit)

  8. Change in Walking Impairment Questionnaire (WIQ) results

    Time frame: 12 months, 24 months, and 36 months

    Mean change in rate from baseline in Walking Impairment Questionnaire (WIQ) results (telephone interview questionnaire)

  9. Proportion of participants with Primary patency

    Time frame: 12 months, 24 months, and 36 months

    Primary patency, defined as freedom from >50% restenosis in the target lesion as indicated by a peak systolic velocity ratio >2.4 on duplex ultrasound or by visual assessment of an angiogram (if patients visit hospital), or freedom from clinically-driven reintervention (if telephone contact)

  10. Proportion of participants with Device Success

    Time frame: Peri-procedural

    Device Success: Successful reaching of the target lesion, inflation and deflation of the balloon catheter, and a final residual stenosis after DCB treatment of ≤30% by visual assessment

  11. Proportion of participants with Procedure Success

    Time frame: Peri-procedural

    Procedure Success: Successful balloon delivery, deployment, and retrieval, with no peri-procedural death, or target vessel revascularization (TVR)

  12. Quality of Life Assessment

    Time frame: 12 months

    Mean change from baseline in European Quality of Life-5 Dimensions (EQ-5D) questionnaire The descriptive system assesses the quality of life and has one question for each of the five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. These answers are combined and converted to an index with 0 for death and 1 for perfect health. The EQ-5D questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).

Sponsors and collaborators

Lead sponsor

OrbusNeich

Industry

Collaborators

  • Centre Européen de Recherche Cardiovasculaire
  • Eucatech AG

Registry information

Official study title

A Prospective PMCF Study of Paclitaxel Drug-coated Balloon Angioplasty for the Treatment of Symptomatic Peripheral Arterial Disease

Important dates

Study start
2025
Primary completion
2027
Study completion
2029
First posted
Feb 18, 2025
Registry last updated
Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.